Novel Adenovirus Vectors for Biodefense Vaccines

描述（由申请人提供）：本提案旨在创建可快速应用于生成针对生物防御威胁剂的新型疫苗的技术。有可能提供防御生物防御威胁的抗原已被确定或正在从独立研究中出现。这项SBIR提案旨在确定能够迅速将这些抗原基因转化为临床试验的有效疫苗的技术平台。现有的腺病毒疫苗平台促进了强大的平衡免疫反应[包括粘膜反应]，并且在GMP生产、制造和质量检测方面有丰富的现有技术诀窍。本SBIR提案的目标是解决当前基于腺病毒血清型5 （Ad5）的腺病毒载体技术的潜在弱点。以前暴露于Ad5病毒或载体并由此产生免疫反应可限制Ad5疫苗载体的效力。因此，艾滋病毒免疫很可能使基于Ad5的载体在其他应用中效力降低。本申请的中心目标是通过建立和测试新的vector疫苗技术平台来扩大腺病毒载体技术的适用性。我们和其他公司目前正在探索用于疫苗应用的非ad5技术。不幸的是，对于生物防御来说，这些第一批非ad5技术也将用于制造艾滋病毒或疟疾疫苗。在本申请中，我们建议开发其他非ad5和非ad35技术用于生物防御疫苗应用。这项SBIR与生产广泛适用或“通用”生物防御技术的努力是一致的。

DESCRIPTION (provided by applicant): This proposal is designed to create technology that can be rapidly applied to the generation of novel vaccines against biodefense threat agents. Antigens that have the potential to provide protection against a biodefense threat have been identified or are emerging from independent research. This SBIR proposal is designed to identify technology platforms that can rapidly convert such antigenic genes into potent vaccines for clinical testing. Existing adenovirus vaccine platforms promote strong balanced immune responses [including mucosal responses] and there is a wealth of existing know-how for GMP production, manufacturing and quality testing. The objectives of this SBIR proposal address a potential weakness in current adenovirus vector technology based on Adenovirus serotype 5 (Ad5). Previous exposure and resulting immune response to Ad5 viruses or vectors can limit the potency of Ad5 vaccine vectors. Consequently, immunization for HIV may well render Ad5 based vectors less potent for other applications. A central goal of this application is to broaden the applicability of adenovirus vector technology by establishing and testing new Advector vaccine technology platforms. We, and others,are currently exploring non-Ad5 technology for vaccine applications. Unfortunately for biodefense, these first non-Ad5 technologies will also be used in the generation of HIV or malaria vaccines. In this application, we propose to develop additional non-Ad5 and non-Ad35 technologies for biodefense vaccine application. This SBIR is aligned with the effort to produce broadly applicable or "Universal," biodefense technology.